Atea Pharma Says FDA Grants Fast Track Designation To AT-752 For Treatment Of Dengue
(RTTNews) - Biopharmaceutical company Atea Pharmaceuticals, Inc. (AVIR) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752, a novel, orally administered, direct-acting antiviral for the treatment of dengue virus infection.
AT-752, a novel, orally administered direct-acting antiviral derived from Atea's purine nucleotide prodrug platform was designed for the treatment and prophylaxis of dengue. It works by impairing the dengue viral polymerase, which then inhibits replication of the virus.
AT-752 is in Phase 2 clinical development and was generally well tolerated in a Phase 1 clinical study. In preclinical studies, AT-752 showed potent in vitro activity against all dengue serotypes, as well as potent in vivo antiviral activity in a small animal model.
For More Such Health News, visit rttnews.com
Atea Pharma Rejects Unsolicited Proposal From Tang Capital Partners
Dollar Extends Losses As Markets Cling On To Fed Cut Hopes
U.S. Homebuilder Confidence Edges Slightly Lower In August
Indian Rupee Rises To 2-week High On GST Reforms Push
Canadian Market May Open Slightly Weak
FTSE 100 Slips After Positive Start, Down Marginally
DAX Drifts Lower; Financials Stocks Among Major Losers
